Skip to content

DMT research published in 2025

Page 3 of 6: studies 41 to 60 of 102, newest first. Back to the DMT overview

Studies

Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.

Journal of Eating Disorders July 24, 2025 Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz et al. 2 citations

There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental...

Complex slow waves in the human brain under 5-MeO-DMT.

Cell Reports July 22, 2025 George Blackburne, Rosalind McAlpine, Marco S. Fabus et al. 10 citations

5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) is a psychedelic drug known for its uniquely profound effects on consciousness; however, it remains unknown how it affects the brain. We collected electroencephalography (EEG) data of 29 healthy individuals before and after inhaling a high dose (12-mg) of vaporized synthetic 5-MeO-DMT. We replicate results from rodents showing amplified low-frequency...

DOI: 10.1016/j.celrep.2025.116040 (opens in new tab) Full text (opens in new tab) Cp: neuroscience Complex dynamics Manifold Slow waves +4

Safety and tolerability of multiple sublingual microdoses of 5-MeO-DMT in adults with moderate symptoms of depression and/or anxiety: a randomized, double-blind, placebo-controlled study.

Neuropsychopharmacology July 15, 2025 Maria Beatriz Bistue Millón, Laura Noguera, Diana Bruno et al. 4 citations

This Phase I clinical trial is the first to rigorously evaluate the safety, tolerability, and pharmacokinetics of a novel sublingual formulation of 5-MeO-DMT, administered at sub-psychedelic doses to adults with moderate to high levels of anxiety and/or depression, without formal psychiatric diagnosis or ongoing treatment. Using a double-blind, placebo-controlled design, participants received a...

Examining the potential of psilocybin and 5-MeO-DMT as therapeutics for traumatic brain injury.

Progress in Neuro-Psychopharmacology and Biological Psychiatry July 14, 2025 Zoe Plummer, Josh Allen, Justin Brand et al. 4 citations

Traumatic brain injury (TBI) is a significant global health challenge, with limited effective treatments for its acute and chronic consequences. TBI is characterized by neuroinflammation, oxidative stress, impaired neuroplasticity, imbalances in neurotransmission, and cell death - factors that contribute to the development of neurological and psychiatric disorders. Emerging evidence suggests...

Fatalities following DMT use: Two case reports and a review of the literature.

Journal of Analytical Toxicology July 9, 2025 Jade Pullen, Robert J. Moore, Rebecca Wood et al. 1 citation

N, N-dimethyltryptamine (DMT) is a hallucinogen found in the South American Psychotria viridis plant and is the major psychoactive ingredient in the brew ayahuasca. In this report we performed a review of the surrounding literature and detail two deaths which recently occurred in the UK following DMT use. A literature search of both academic (PubMed, GoogleScholar) and media (using Google...

Population pharmacokinetic-pharmacodynamic modeling of co-administered N,N-dimethyltryptamine and harmine in healthy subjects.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie July 9, 2025 Angela Äbelö, John W Smallridge, Robin von Rotz et al. 3 citations

N,N-dimethyltryptamine (DMT) is a psychedelic compound commonly co-administered with the monoamine oxidase inhibitor harmine in ayahuasca-inspired formulations. However, the impact of harmine on DMT pharmacokinetics (PK) and pharmacodynamics (PD) remains insufficiently characterized. In this single-blind, randomized, two-arm, factorial, dose-finding study, 16 healthy participants (9 males, 7...

DOI: 10.1016/j.biopha.2025.118329 (opens in new tab) Full text (opens in new tab) Pharmacodynamics Pharmacokinetics Psychedelics Harmine-DMT Interaction Alter +10

Unraveling the policies, legislations, and regulations of psychedelics in Australia, Canada, Netherlands, New Zealand, and India.

Health policy (Amsterdam, Netherlands) July 8, 2025 Ramesh Joga, Sravani Yerram, Jayasri Devi Patnam et al. 5 citations

Research into psychedelics has gained renewed interest due to their potential to address psychiatric, neurological, and other peripheral conditions. These substances offer long-term therapeutic benefits, contrasting with the side effects and limitations of current psychiatric medicines. This study examines the legislations and regulatory frameworks for psychedelics in Australia, Canada, The...

Disintegration of Default Mode: Functional MRI Insights Into N,N-Dimethyltryptamine (DMT), Consciousness, and Subcortical Connectivity.

Cureus July 1, 2025 Amy Avakian

N,N-Dimethyltryptamine (DMT), a potent endogenous psychedelic, evokes rapid and immersive shifts in consciousness that challenge conventional neurocognitive models. Functional magnetic resonance imaging (fMRI) and electroencephalography (EEG)-fMRI studies suggest that these altered states are not chaotic but patterned, marked by a disruption of the default mode network (DMN), an increase in...

DOI: 10.7759/cureus.88931 (opens in new tab) Full text (opens in new tab) FMRI Neuroimaging Functional MRI FMRI Pituitary DMT Dmn

Synthesis of Psilocin, Psilocybin and 5‐MeO‐DMT Succinate, All Labelled With Carbon‐14 at the Indole 2‐Position

Journal of Labelled Compounds and Radiopharmaceuticals July 1, 2025 Rodney D. Brown, Niall M. Hamilton, Connor Mallon et al. 1 citation

ABSTRACT Three novel 14 C‐labelled isotopologues of the psychoactive agents psilocin, psilocybin and 5‐methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) were synthesised, all labelled at the 2‐position of the indole. The syntheses involved incorporating the 3‐dimethylaminoethyl substituent common to all three substances onto a 4‐ or 5‐substituted indole intermediate via successive treatments with...

DOI: 10.1002/jlcr.4155 (opens in new tab) Psilocybin Tryptamines Indole test Oxalyl chloride +6

We licked the frogs so you don’t have to: A comprehensive history and analysis of the chemical syntheses of the classical psychedelics Bufotenin(e) and 5-methoxy-N,N-dimethyltryptamine

ChemRxiv June 26, 2025 Anton A. Homon, Jaxon Laramie, John J. Hayward et al. preprint

Bufotenin (also spelt as bufotenine) and its methylated derivative, 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) are potent psychedelics (although the activity of the former is attenuated due to its low propensity to cross the blood-brain-barrier) that are found in many plants but also excreted by specific species of toads. The compounds are regulated differently around the world, and although...

Fear as medicine: A mixed-methods analysis of 5-MeO-DMT, mental health, and intergenerational healing

Applied Psychology Research June 26, 2025 Jeffrey Overall

Objective: This study investigates the psychological mechanisms through which 5-methoxy-N, N-dimethyltryptamine (5-MeO-DMT) influences mental health outcomes, with a focus on fear confrontation, emotional release, and intergenerational trauma. Design: A qualitative methodology was employed, combining grounded theory and qualitative comparative analysis (QCA). Fourteen individuals who had...

Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects

Universität Zürich, ZORA June 19, 2025 Helena Dorothea Aicher, Ilhui A Wicki, Daniel Meling et al.

Background: Mindfulness and compassion are therapeutically relevant and can be increased through different forms of meditation practices. However, meditation practice needs time and commitment. These resources are often limited in patients with mood disorders. Therefore, efficacious remedies that increase mindfulness and compassion could provide therapeutic options. This study aimed to...

DOI: 10.5167/uzh-284146 (opens in new tab) Randomized controlled trial Self-compassion Mindfulness meditation Placebo +4

Investigating the Synergistic Neuroprotective Effects of Plant-Derived Antioxidants and the Psychedelic N,N-Dimethyltryptamine in Alzheimer's Disease Therapy.

Cells June 19, 2025 Júlia Jarne-Ferrer, Mercè Pallàs, Christian Griñán-Ferré et al. 2 citations

Alzheimer's disease (AD) is a chronic and complex neurodegenerative disorder characterized by progressive cognitive decline, memory loss, and irreversible impairment of brain functions. The etiology of AD is multifactorial, involving a complex interplay of genetic, environmental, and physiological factors, including the aggregation of amyloid-β (Aβ) and oxidative stress (OS). The role of OS in...

Enhancing mindfulness and compassion through an ayahuasca-inspired formulation containing N,N-DMT and harmine: A randomized controlled trial in healthy subjects.

Journal of Psychopharmacology June 19, 2025 Helena Aicher, Ilhui A Wicki, Daniel Meling et al. 2 citations

Mindfulness and compassion are therapeutically relevant and can be increased through different forms of meditation practices. However, meditation practice needs time and commitment. These resources are often limited in patients with mood disorders. Therefore, efficacious remedies that increase mindfulness and compassion could provide therapeutic options. This study aimed to investigate the...

Safety, tolerability and subjective effects of vaporized N,N-Dimethyltryptamine: A randomized double-blind clinical trial.

European Neuropsychopharmacology June 17, 2025 Isabel Wießner, Marcelo Falchi-Carvalho, Sophie Laborde et al. 7 citations

Vaporized N,N-Dimethyltryptamine (DMT) has a short duration and simple application, prompting this technique as a new approach for psychedelics' clinical use. Building on our initial dose-ascending studies and addressing potential confounding effects of dosing order, this study is the first to evaluate inhaled DMT in a randomized, placebo-controlled, double-blind design. Given DMT's therapeutic...

DOI: 10.1016/j.euroneuro.2025.06.002 (opens in new tab) Full text (opens in new tab) Psychedelic therapy N,N-Dimethyltryptamine Placebo-controlled study Psychedelics +17

Treating War Trauma with Ibogaine and 5-MEO-DMT

June 16, 2025 María José Polanco, Mark D. Black

This chapter details the therapy protocols involving ibogaine utilized at The Mission Within (https://missionwithin.org) in Baja California, Mexico, as described by its founder and research director, Dr. Martin Polanco, along with psychedelic preparation/integration counselor and therapeutic facilitator, Dr. Mia Black. The chapter describes: Their personal development as ibogaine therapists and...

Optimized Parenteral and Intranasal Formulations of Tryptamine Psychedelics for Rapid-Acting Antidepressant Therapy.

ACS Medicinal Chemistry Letters June 12, 2025 Robert B. Kargbo 1 citation

Innovative formulations of N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) enable parenteral and intranasal delivery, respectively. These delivery systems overcome limitations of poor bioavailability and rapid metabolism, offering rapid-onset, short-duration therapeutic effects. The compositions support controlled psychedelic interventions for psychiatric...

Immunomodulatory and behavioral effects of ayahuasca and N, N-dimethyltryptamine in a rat model of lipopolysaccharide-induced depression.

Metabolic Brain Disease June 11, 2025 Daniel do Nascimento Sousa, Monique de Azevedo, Maria Lucília Santos et al. 5 citations

Ayahuasca (Aya) is an Amazonian beverage traditionally used as medicine by Indigenous people in South America to treat various illnesses and have shown a potential to treat depression. This study aimed to investigate the antidepressant effects of fluoxetine, Aya and N, N dimethyl tryptamine (DMT), a component of the beverage, focusing on the modulation of inflammatory serum cytokine profiles...

Safety and tolerability of NN-dimethyltryptamine (DMT) in healthy volunteers and Major Depressive Disorder (MDD) patients: A systematic review of early-phase clinical trials.

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 7, 2025 Damian Swieczkowski, Aleksander Kwaśny, Wiesław Jerzy Cubała 5 citations

Treatment-resistant depression (TRD) remains a challenge, with many patients unresponsive to standard antidepressants. NN-dimethyltryptamine (DMT), a fast-acting psychedelic, offers potential benefits due to its rapid onset and short duration. This review, registered with the Open Science Framework (DOI: 10.17605/OSF.IO/6D9WC), summarizes the safety and tolerability of DMT in early-phase...

DOI: 10.1016/j.pnpbp.2025.111419 (opens in new tab) Full text (opens in new tab) Nn-Dimethyltryptamine DMT Systematic review Treatment resistant depression Psychedelics hallucinogens +4

Request for Proposals - Exploring expanded consciousness and endogenous DMT

June 5, 2025 Tyler C. Diorio

Request for Proposals - Exploring expanded consciousness and endogenous DMT Sponsor: DMT Quest Aim of Funding This funding seeks to advance scientific understanding of consciousness, human potential, and the mechanisms underlying expanded awareness. Eligible research may investigate endogenous N,N-dimethyltryptamine (DMT) and its role in human consciousness, but we also welcome innovative...